Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Kissei Pharmaceutical
Thumbnail
March 21, 2022

Biohaven’s high-risk bet

There are long shots and then there is troriluzole. Biohaven will soon find out if it was wise to press on with the asset.

Thumbnail
March 01, 2021

Early Morphic data hint at a threat to Entyvio

Hopes rise that Morphic might have cracked the conundrum of oral integrin inhibitors.

Article image
Vantage logo
December 06, 2018

Bayer puts the brakes on vilaprisan trials following safety concerns

The decision to halt trials for the uterine fibroid product marks another setback in an area where there are few suitable solutions for patients.

Article image
Vantage logo
October 19, 2018

Abbvie makes a big bet on preclinical integrin inhibitors

Vantage logo
October 04, 2017

Therapy focus – No safe haven for bio in spinocerebellar ataxia

Vantage logo
May 19, 2015

Dry eye development reaches the Eleventh hour

Vantage logo
April 23, 2015

GSK labours the point of addressing the unloved unmet needs

Vantage logo
August 06, 2014

Waiting game continues with Mircera launch

Vantage logo
January 03, 2014

Pharma business development news over Christmas

Vantage logo
March 05, 2013

Lexicon could define Sanofi as the ideal diabetes partner

Vantage logo
April 13, 2012

Therapeutic focus - Amgen buys novel kidney disease treatment as bundling bites

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 12, 2022

Q2 Roundup Infographic

August 10, 2022

Q2 Roundup eBook

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.